335 related articles for article (PubMed ID: 38496700)
1. Clinical translation for targeting DNA damage repair in non-small cell lung cancer: a review.
Mao X; Lee NK; Saad SE; Fong IL
Transl Lung Cancer Res; 2024 Feb; 13(2):375-397. PubMed ID: 38496700
[TBL] [Abstract][Full Text] [Related]
2. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
Cerrato A; Morra F; Celetti A
J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
[TBL] [Abstract][Full Text] [Related]
3. Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations.
Ngoi NYL; Westin SN; Yap TA
Curr Opin Oncol; 2022 Sep; 34(5):559-569. PubMed ID: 35787597
[TBL] [Abstract][Full Text] [Related]
4. Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy.
Gourley C; Balmaña J; Ledermann JA; Serra V; Dent R; Loibl S; Pujade-Lauraine E; Boulton SJ
J Clin Oncol; 2019 Sep; 37(25):2257-2269. PubMed ID: 31050911
[TBL] [Abstract][Full Text] [Related]
5. Targeting DNA repair pathway in cancer: Mechanisms and clinical application.
Wang M; Chen S; Ao D
MedComm (2020); 2021 Dec; 2(4):654-691. PubMed ID: 34977872
[TBL] [Abstract][Full Text] [Related]
6. State-of-the-art strategies for targeting the DNA damage response in cancer.
Pilié PG; Tang C; Mills GB; Yap TA
Nat Rev Clin Oncol; 2019 Feb; 16(2):81-104. PubMed ID: 30356138
[TBL] [Abstract][Full Text] [Related]
7. Predictive and Prognostic Value of DNA Damage Response Associated Kinases in Solid Tumors.
Gachechiladze M; Skarda J; Bouchalova K; Soltermann A; Joerger M
Front Oncol; 2020; 10():581217. PubMed ID: 33224881
[TBL] [Abstract][Full Text] [Related]
8. Everything Comes with a Price: The Toxicity Profile of DNA-Damage Response Targeting Agents.
Martorana F; Da Silva LA; Sessa C; Colombo I
Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205700
[TBL] [Abstract][Full Text] [Related]
9. Targeting the DNA Damage Response Machinery for Lung Cancer Treatment.
Venugopala KN
Pharmaceuticals (Basel); 2022 Nov; 15(12):. PubMed ID: 36558926
[TBL] [Abstract][Full Text] [Related]
10. Evolving DNA repair synthetic lethality targets in cancer.
Kulkarni S; Brownlie J; Jeyapalan JN; Mongan NP; Rakha EA; Madhusudan S
Biosci Rep; 2022 Dec; 42(12):. PubMed ID: 36420962
[TBL] [Abstract][Full Text] [Related]
11. Targeting DNA Damage Response in Prostate and Breast Cancer.
Wengner AM; Scholz A; Haendler B
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33158305
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic Targeting of DNA Damage Response in Cancer.
Choi W; Lee ES
Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163621
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in DDR (DNA damage response) inhibitors for cancer therapy.
Cheng B; Pan W; Xing Y; Xiao Y; Chen J; Xu Z
Eur J Med Chem; 2022 Feb; 230():114109. PubMed ID: 35051747
[TBL] [Abstract][Full Text] [Related]
14. DNA Damage Repair Inhibitors-Combination Therapies.
Smith G; Alholm Z; Coleman RL; Monk BJ
Cancer J; 2021 Nov-Dec 01; 27(6):501-505. PubMed ID: 34904813
[TBL] [Abstract][Full Text] [Related]
15. Targeting DNA damage repair pathways in pancreas cancer.
Crowley F; Park W; O'Reilly EM
Cancer Metastasis Rev; 2021 Sep; 40(3):891-908. PubMed ID: 34403012
[TBL] [Abstract][Full Text] [Related]
16. Targeting the DNA damage response for cancer therapy.
Curtin NJ
Biochem Soc Trans; 2023 Feb; 51(1):207-221. PubMed ID: 36606678
[TBL] [Abstract][Full Text] [Related]
17. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
18. New perspective on DNA response pathway (DDR) in glioblastoma, focus on classic biomarkers and emerging roles of ncRNAs.
Pirlog BO; Ilut S; Pirlog R; Chiroi P; Nutu A; Radutiu DI; Cuc GD; Berindan-Neagoe I; Nabavi SF; Filosa R; Nabavi SM
Expert Rev Mol Med; 2023 May; 25():e18. PubMed ID: 37154101
[TBL] [Abstract][Full Text] [Related]
19. Targeting DNA Damage Repair for Immune Checkpoint Inhibition: Mechanisms and Potential Clinical Applications.
Sun W; Zhang Q; Wang R; Li Y; Sun Y; Yang L
Front Oncol; 2021; 11():648687. PubMed ID: 34026622
[TBL] [Abstract][Full Text] [Related]
20. Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal Cancer.
Deng S; Vlatkovic T; Li M; Zhan T; Veldwijk MR; Herskind C
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]